Remnant pancreatic carcinoma: The current status

Table 1 Chemotherapy in pancreatic cancer

Trial	Year	Drug regimen	DFS (months)	OS (months)
ESPAC-1[38]	2001	5FU vs observation	15.3 vs 9.4 (P = 0.02)	20.1 vs 15.5
CONKO-001[39]	2007	Gemcitabine vs observation	13.4 vs 6.9 (P < 0.001)	22.8 vs 20.2
ESPAC-3[40]	2010	5FU vs gemcitabine	14.1 vs 14.3 (P = 0.53)	23.0 vs 23.6
CONKO-005[41]	2017	Gemcitabine vs erlotinib	11.4 vs 11.4 (P = 0.26)	26.5 vs 24.5
ESPAC-4[42]	2017	Gemcitabine vs capecitabine	13.1 vs 13.9 (P = 0.082)	25.5 vs 28.0
PRODIGE 24[43]	2018	Gemcitabine vs FOLFIRINOX	12.8 vs 21.6 (P < 0.001)	35.0 vs 54.4
APACT[44]	2019	Gemcitabine vs gemcitabine + nab	13.7 vs 16.6	36.2 vs 40.5

5FU: 5-fluorouracil; DFS: Disease free survival; OS: Overall survival.